Ignite Creation Date:
2024-05-06 @ 12:30 AM
Last Modification Date:
2024-10-26 @ 10:51 AM
Study NCT ID:
NCT01598025
Status:
TERMINATED
Last Update Posted:
2018-08-09
First Post:
2012-05-09
Brief Title:
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Closed due to poor accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Approximately 30 of patients who are candidates for bone marrow transplants do not have an HLA-matched or close to matched donor available For this reason doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors
This study is being done to test the safety and the treatment results of a specific kind of transplant In this transplant blood from two donors will be used Each donor will share one half of your HLA type Blood from both donors will be transplanted at the same time
This study is being done to test the safety and the treatment results of a specific kind of transplant In this transplant blood from two donors will be used Each donor will share one half of your HLA type Blood from both donors will be transplanted at the same time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None